http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
흰쥐에서 UDCA와 Silymarin을 함유한 간장질환 치료용 의약조성물(DWP305)의 담즙 및 요중 배설
남권호(Kweon Ho Nam),김동오(Dong O Kim),조재열(Jae Youl Cho),염제호(Je Ho Yeom),김영만(Young Man Kim),유은숙(Eun Sook Yoo),유영효(Young Hyo Yu),박명환(Myung Hwan Park) 대한약학회 1994 약학회지 Vol.38 No.6
The pharmacokinetics of DWP305, a new combined preparation for hepatic disorders was examined in rats. DWP305 was composed of ursodeoxycholic acid(UDCA), Cardus marianus extract(silymarin 74.5%), fursulthiamine and riboflavin tetrabutyrate(RTB). Especially, this study was focused on, the possibilities of drug interaction that the administration of DWP305 may affect the oral absorption of each component. After oral administration of DWP305 and each component drug to rats, the biliary excretion of silybin and tauroursodeoxycholic acid(TLJDCA), and the urinary excretion of vitamins were measured by HPLC up to 48 hours. The cumulative amount of TLTDCA or silybin in bile was not significantly different between DWP305 and UDCA/silymarin administered groups at doses of 25 and 100mg/kg. In the case of vitamin study, the urinary thiamine excretion of equivalent molar fursulthiamine administered group was significantly higher than that of thiamine administered group. Urinary riboflavin level of equivalent molar RTB administered group was lower than that of riboflavin administered group, but not significant. These results suggest that the combined preparation may not affect the oral absorption of each component in respect of drug in teraction. Also, fursulthiamine and RTB were more effective in oral absorption than thiamine and riboflavin, respectively.
흰쥐에 재조합 인간 상피세포 성장인자(DWP401)를 연용피하투여했을 때 약물체내동태
남권호(Kweon Ho Nam),조재열(Jae Youl Cho),정주영(Joo Young Chung),장우익(Woo Ik Chang),강진석(Jin Seok Kang),유은숙(Eun Sook Yoo),박승국(Seung Kook Park),유영효(Young Hyo Yu),박명환(Myung Hwan Park),심창구(Chang Koo Shim) 대한약학회 1996 약학회지 Vol.40 No.5
The organ distribution and pharmacokinetics of DWP401, a recombinant human epidermal growth factor (rhEGF), were compared after single and repeated subcutaneous administration (50mcg/kg, 10mcCi/kg of 125I-DWP401, twice a day for 7 consecutive days) to rats. The pharmacokinetic parameters such as AUC and terminal half-life were similar between two different administration. During repeated administration, the plasma concentration of DWP401 seemed to be constant when the plasma was collected at 15 min after each dosing. The TCA-precipitated radioactivities in thyroid, liver, kidney, and stomach were higher than those of other organs studied after both single and repeated administration. The TCA-precipitated radioactivities after repeated administration in several organs, such as thyroid, stomach, prostate, adrenal, eye ball, and testis were higher than those after single administration. But, according to the observations using gel filtration chromatography and antibody binding assay, the radioactivities in thyroid and stomach were not primarily due to the intact DWP401 or its metabolites but due to the 125I-thyroxine binding protein. In conclusion, it can be suggested that DWP401 is metabolized to each amino acid or small polypeptides, and there was no significant changes in pharmacokinetics or any indications for accumulation of DWP401 in rat plasma and organs after repeated treatment.
유제화에 의한 경구용 항암제인 테가푸르의 장관 임파수송
이용복,남권호,장우익,오인준,고익배,Lee, Yong-Bok,Nam, Kweon-Ho,Chang, Woo-Ik,Oh, In-Joon,Koh, Ik-Bae 한국약제학회 1995 Journal of Pharmaceutical Investigation Vol.25 No.1
W/O and O/W emulsions of tegafur (50 mg/5 ml/kg) were orally administered to rats to compare with their mesenteric lymphatic delivery effects. And also in order to demonstrate the lymph targeting associated to the oral route, it was deemed necessary to investigate the fate of solution after oral administration as a control. Lymph and plasma samples were periodically taken from each subject of mesenteric lymphatic duct cannulated rats. Then, lymph and plasma levels of tegafur and its active metabolite, 5-FU, were simultaneously observed. Also pharmacokinetic parameters were compared with each others. On the other hand, most previous studies of lymphatic transport have not addressed the question of whether an increase in mesenteric or thoracic lymph transport by the manipulation of a suspected variable was due to a selective delivery to the intestinal lymphatics or an overall increase availability. Therefore, based on a physiologically based pharmacokinetic model which represents the characteristics of lymphatic systems, we are also going to determine the contributions of mesenteric lymph transport versus thoracic lymph transport of tegafur reported in reference(13). In comparison with tegafur solution, AUC and mean residence time of plasma tegafur were significantly increased in W/O emulsion but significantly decreased in O/W emulsion. Lymph flow rates were similar in both solution and W/O emulsion but half in O/W emulsion. AUC of tegafur in mesenteric lymph and in plasma for W/O emulsion were 3.7 times and 2.9 times more than those for O/W emulsion, respectively. And AUC of 5-FU in thoracic lymph for W/O emulsion was 3.7 times more than that for O/W emulsion. These results suggested that lymphatic delivery or tegafur by W/O emulsion was more effective than that by on emulsion due to its differences or formation ability of chylomicrons.
Polyoxyl 40 Hydrogenated Castor Oil 이 실리마린과 우루소데옥시콜린산 복합제제중 실리마린의 용해성 및 생체이용률에 미치는 영향
장우익(Woo Ik Chang),남권호(Kweon Ho Nam),조재열(Jae Youl Cho),이재휘(Jae Hwi Lee),유영효(Young Hyo Yu),박명환(Myung Hwan Park),김재환(Jae Hwan Kim) 한국응용약물학회 1997 Biomolecules & Therapeutics(구 응용약물학회지) Vol.5 No.3
The effect of nonionic surfactant(polyoxyl 40 hydrogenated castor oil, PHCO), a common solubilizer, on the solubility of silymarin in the combined preparation containing ursodeoxycholic acid(UDCA) and silymarin was investigated in vitro using HPLC. The solubility of silybin, a major component of silymarin, was enhanced by increasing the amount of PHCO. The effect of PHCO on bioavailability was also evaluated in rats. The bioavailability was calculated by silybin content in bile juice that was excreted for 24 hr after oral administration. It was found that the bioavailability of silymarin containing PHCO was significantly increased compared to that of control. These results suggest that PHCO may improve the solubility and bioavailabilty of silymarin when it is combined with UDCA and silymarin.
C7위치에 3-아미노-4-메칠치오메칠피로리디닐기를 치환한 신규 퀴놀론계 항생물질 DWP10349 및 DWP20351의 흰쥐에서의 체내동태 및 조직분포
조재열(Jae Youl Cho),남권호(Kweon Ho Nam),유은숙(Eun Sook Yoo),이재욱(Jae Wook Lee),유영효(Young Hyo Yu),박명환(Myung Hwan Park) 대한약학회 1997 약학회지 Vol.41 No.3
Pharmacokinetics and tissue distribution of DWP20349 and 20351, new quinolones, were examined in rats after a single intravenous and oral administration. Analyses of DWP20349 and DWP20351 in plasma, tissue, and urine were determined by both HPLC and bioassay(microbiological assay). The plasma concentrations of the drugs declined biexponentially. The terminal half-lives (t1/2beta) of drugs were about 114 min (DWP20349) and 105 min (DWP20351) after intravenous dosing, and were 77 min (DWP20349) and 79 min (DWP20351) after oral dosing. The volume of distrbution at steady-state (Vdss) and total body clearances (Clt) of DWP20349 and DWP20351 were 760 ml/kg and 1126 ml/kg, and 5ml/min/kg and 10 ml/min/kg, respectively. The extents of bioavailability if DWP20349 and DWP20351 after oral administration were 29% and 28%, respectively. 24 h urinary recoveries measured by bioassay were 1.8% (DWP20349) and 1.3% (DWP20351) after oral dosing, and 2.4% (DWP20349) and 1.9% (DWP20351) after intravenous dosing. Plasma protein binding ratios ranged from 87%-90% (DWP20349) and 61%-68% (DWP20351). These drugs were highly distrbuted by the order of lung, kidney, liver and plasma (DWP20394), and lung, liver, kidney and plasma (DWP20351) after 1 hour orally administered.
흰쥐에서 제산제와 병용투여된 아세글루타미드 알루미늄의 약물동태 및 위장관 부착
조재열(Jae Youl Cho),남권호(Kweon Ho Nam),유은숙(Eun Sook Yoo),유영효(Young Hyo Yu),박명환(Myung Hwan Park),박정일(Jeong Hill Park) 대한약학회 1995 약학회지 Vol.39 No.6
On the combination of antacid, the pharmacokinetics and gastric adhesion of [14C]aceglutamide aluminium complex([14C]AGA) were examined in rats. Specially, this study was focused on the drug interaction that the co-administration of anatacid may affect the oral co-administration of [14C] AGA and antacid(aluminium hydroxide and magnesium hydroxide(AM)), the radioactivity of plasma and urinary recovery was lower than that of [14C]AGA alone administered group. However, the cumulative recovery of radioactivity in feces was increased significantly. The comparative bioavailability of [14C]AGA from the plasma concentration-time curve and urinary recovery was about 60%. In vitro, the effect of antacid on the gastric adhesion of AGA was not significantly different between AGA and AGA/antacid treatment. And it accorded well with the result of in vivo experiment. In conclusion, on the combination of antacid , the oral absorption of AGA was decreased but the gastric adhesion was not affected in respect of drug interaction.
신규 퀴놀론계 항생물질 DWQ-013의 흰쥐 및 생쥐에서의 체내동태
조재열(Jae Youl Cho),남권호(Kweon Ho Nam),김동오(Dong O Kim),이종완(Jong Wan Lee),박남준(Nam Joon park),강영숙(Young Sook Kang),유영효(Young Hyo Yu),이재욱(Jae wook Lee) 대한약학회 1995 약학회지 Vol.39 No.3
The pharmacokinetics and tissue distribution of DWQ-013, a new quinolone, were examined in rats and mice following a single intravenous and oral administration. DWQ-013 in plasma and urine was determined by both HPLC and microbiological assay. The plasma concentration of the drug declined biexpohentially. The terminal half life of the drug was 1.11 +/- 0.14 hour after intravenous dosing. The volume of distribution at terminal elimination phase(Vdbeta) and total clearance of the drug were 1.29 +/- 0.15l/kg and 0.78 +/- 0.09 l/h/kg. The bioavailability of DWQ-013 after oral administration was 56.0%(HPLC) and 77.2%(bioassay), respectively. Twelve-hour urinary recovery of drug was measured by HPLC and bioassay to 0.035 +/- 0.009% and 4.71 +/- 0.66% after oral dosing, to 0.055 +/- 0.014% and 7.65 +/- 1.53% after intravenous dosing, which may indicate the presence of biologically active metabolites. Binding of the drug to plasma proteins ranged from 97%-99% at various concentrations. The drug was highly distributed in order of liver, kidney and lung after 1.5 hours in mice.
Micro-PIV Measurement of Abnormal Cardiac Outflow in a Hypothermic Chicken Embryo
Eunseop Yeom(염은섭),Kweon-Ho Nam(남권호),Hojin Ha(하호진),Sang-Joon Lee(이상준) 대한기계학회 2010 대한기계학회 춘추학술대회 Vol.2010 No.11
Blood in the outflow tract (OFT) of a chicken embryonic heart exhibits highly variable flow pattern depending on the change of heart shape during the variation of developmental stages and variation of environmental conditions. In this study, the pulsatile blood flow in the OFT of a chicken embryonic heart was investigated experimentally using a micro PIV technique. Microscopic images were consecutively captured from a chicken embryo at HH stage 17 (2.5 days of incubation) and stored for PIV analysis. Red blood cells (RBCs) were directly used as flow tracers. When the heart is exposed to room temperature, reflux occurs during the diastole. This results from the inharmonic heart movement under hypothermic condition and the undeveloped heart valve at this developmental stage. The peak velocity and heart rate are lower than those of normal embryonic heart. The comparative study on the blood flows in the OFT of a chicken embryonic heart for both normal and abnormal conditions would be helpful to understand the corresponding hemodynamic characteristics and develop a valveless biomimetic pump system.